Mini-Sentinel Project Will Evaluate Impact Of LABA Label Change
Executive Summary
The Mini-Sentinel medical products safety surveillance project will assess the health impact of FDA-mandated label warnings for use of long-acting beta agonists in asthma, Harvard Pilgrim Health Care Institute’s Richard Platt noted during a Sept. 15 webinar on Mini-Sentinel sponsored by the Brookings Institution.
You may also be interested in...
Do Black Boxes Work? US FDA Survey Would Test Impact On Prescribers
Depending on who you ask, black box warnings can fail to curb inappropriate prescribing or scare off patients who would benefit from an effective therapy. FDA is proposing a provider survey to find out what perceptions really are.
Do Black Boxes Work? US FDA Survey Would Test Impact On Prescribers
Depending on who you ask, black box warnings can fail to curb inappropriate prescribing or scare off patients who would benefit from an effective therapy. FDA is proposing a provider survey to find out what perceptions really are.
Asthma Warnings Not Working Well, FDA Fears As GSK Seeks Expanded LABA Approval
LABA prescribing patterns haven’t changed despite FDA’s labeling instructions on asthma safety concerns, agency concludes.